First-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NICReWo Trial)
RecruitingOBSERVATIONAL
Enrollment
300
Participants
Timeline
Start Date
January 17, 2025
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2027
Conditions
Non Small Cell Lung Cancer Metastatic
Trial Locations (1)
27100
RECRUITING
Fondazione IRCCS Policlinico San Matteo, Pavia
All Listed Sponsors
lead
Fondazione IRCCS Policlinico San Matteo di Pavia
OTHER
NCT07190677 - First-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NICReWo Trial) | Biotech Hunter | Biotech Hunter